BeOne Medicines account plan
global oncology drug development
At a glance
BeOne Medicines (formerly BeiGene) is a global oncology company behind BRUKINSA: FY2025 revenue $5.3 billion, nearly 12,000 employees.
BeOne Medicines, formerly BeiGene, is a global oncology company that discovers, develops, manufactures and sells cancer medicines, led by the BTK inhibitor BRUKINSA and the anti-PD-1 antibody TEVIMBRA, plus in-licensed products sold mainly in China. Founded in 2010, it redomiciled to Switzerland (registered office in Basel) in 2025, operates through subsidiaries in the U.S., China, the UK and Australia, and is listed on Nasdaq, HKEx and the Shanghai STAR board. FY2025 total revenue was $5,343.0 million (+40.2%), with net income of $286.9 million, its first year of GAAP profit, and free cash flow of $941.7 million; the U.S. contributed $2,880.3 million and China $1,679.5 million. It had nearly 12,000 full-time employees as of February 13, 2026, about 1,900 of them in the U.S.
Business units
Hematology franchise (BRUKINSA, BEQALZI, tacabrutideg)
about 73.5% of FY2025 total revenue (BRUKINSA $3,928.5 million)BRUKINSA (zanubrutinib) is a BTK inhibitor approved in 77 markets across five B-cell malignancy indications and became the global leader in its class in 2025; Q3 2026 sales were $1,390.9 million (+33.7%), with U.S. sales above $1 billion in a quarter for the first time. BEQALZI (sonrotoclax), a BCL2 inhibitor, is approved in China and by the FDA in mantle cell lymphoma, and the BTK degrader tacabrutideg targets a submission in mid-2027.
Solid tumors (TEVIMBRA and pipeline)
about 13.8% of FY2025 total revenue (TEVIMBRA $737.3 million)TEVIMBRA (tislelizumab) is an anti-PD-1 antibody approved in 51 markets; Q3 2026 sales rose 27.6% to $243.3 million, and the FDA approved it with ZIIHERA and chemotherapy in 1L HER2+ gastric and GEA cancer in August 2026. Five programs (GPC3 x 4-1BB bispecific, PRMT5 inhibitor, CEA ADC, CDK4 inhibitor, B7-H4 ADC) are moving toward registration in breast, lung, gastrointestinal and ovarian cancers.
In-licensed products, mainly in China
about 9.1% of FY2025 total revenue (Amgen products)BeOne sells Amgen's XGEVA ($306.0 million), BLINCYTO ($104.2 million) and KYPROLIS ($75.0 million in 2025) in mainland China with profits shared equally, plus products from Jazz/Zymeworks, Recordati, Bio-Thera, Luye and Novartis. Amgen products in China grew 25.5% to $167.0 million in Q3 2026, while KYPROLIS fell 24.3% and POBEVCY promotion is being discontinued.
Other revenue (royalties)
about 1.1% of FY2025 total revenue ($61.0 million)Mainly Amgen royalties on IMDELLTRA sales outside China and Novartis broad markets revenue; a significant portion of the IMDELLTRA royalty rights was sold to Royalty Pharma in 2025.
Strategic priorities
- Lead in CLL with three mechanisms
- Build a hematology franchise on BRUKINSA, BEQALZI and tacabrutideg, targeting leadership in the approximately $12 billion global CLL market, with registrational programs in treatment-naive and relapsed settings.
- Expand BRUKINSA into 1L mantle cell lymphoma
- The MANGROVE filing (BRUKINSA plus rituximab) has FDA Priority Review and was submitted in the EU and China, with a Japan submission in Q4 2026.
- Make 2026 a solid tumor inflection year
- Five solid tumor programs reached proof of concept, with Phase 3 starts in HCC in Q4 2026 and 1H 2027, a B7-H4 ADC Phase 3 in ovarian cancer and a CDK4 Phase 3 upsized to 1,200 patients.
- Grow TEVIMBRA globally
- Expand TEVIMBRA's footprint and build global commercial capabilities, with China decisions on TEVIMBRA and ZIIHERA in 1L HER2+ GEA expected in 1H 2027.
- Disciplined growth with measured margin expansion
- Raised FY2026 guidance to $6.9-7.0 billion revenue and $1.2-1.3 billion GAAP operating income; the CFO expects margin expansion in 2027 to be modest as operating expenses keep growing.
Latest results
In Q3 2026 total revenue rose 33.8% to $1,889.8 million, with BRUKINSA up 33.7% to $1,390.9 million and TEVIMBRA up 27.6% to $243.3 million. Income from operations grew 156.7% to $418.7 million and net income 208.2% to $384.7 million, while free cash flow was $473.5 million; the gross margin on product sales reached 88.3%. Nine-month revenue was $5,108.3 million (+32.9%). BeOne raised its FY2026 guidance to total revenue of $6.9-7.0 billion and expects a tax valuation allowance reversal in Q4 2026.
Investments and deals
- Hopewell, New Jersey expansion
- A $300 million expansion of the Hopewell biologics site was announced in 2026, adding to a 42-acre site with 8,000 liters of capacity opened in July 2024.
- Revolution Medicines collaboration
- Signed August 10, 2026: combination trials with its four clinical RAS(ON) inhibitors and exclusive rights to those assets in select Asian markets.
- R&D spending
- R&D was $2,145.9 million in 2025 and rose 26.2% to $660.8 million in Q3 2026 as programs moved to late stage; an in-house clinical team of about 3,800 people runs trials largely without CROs.
- Royalty and debt financing
- Royalty Pharma paid $885 million upfront for IMDELLTRA royalties, and a November 2025 HSBC-led Facilities Agreement refinanced about $768 million of short-term loans.
- U.S. access and manufacturing agreement
- A voluntary agreement with the U.S. government on August 31, 2026 to expand access to cancer medicines and strengthen the U.S. manufacturing footprint.
Challenges and risks
- Competition in BTK and PD-1 classes
- BRUKINSA competes with acalabrutinib, ibrutinib and pirtobrutinib, and TEVIMBRA faces steep competition in China; CELESTIAL-301 missed uMRD superiority versus VO.
- Pricing and reimbursement pressure
- The U.S. Inflation Reduction Act, a Medicare Part D liability increase expected to be a flat to modest headwind in 2027, and China's NRDL and volume-based procurement.
- In-licensed product erosion in China
- XGEVA biosimilars and potential VBP inclusion for XGEVA and KYPROLIS will likely pressure revenue beyond 2026.
- U.S.-China relations
- PRC government policy, U.S.-China relations and CSRC filing requirements are named risks for a company with large operations in both countries.
- Dependence on distributors and CMOs
- Cencora (18.5%), McKesson (17.5%) and Shanghai Pharmaceutical (10.1%) accounted for large shares of 2025 product revenue, and BeOne relies on contract manufacturers.
What leadership says
“Across every dimension of the business, BeOne is executing at the very highest level in our history.”
“we are living up to our promise that 2026 would be an inflection year”
“the pace of margin expansion is likely to be modest as compared to 2025 and 2026”
“building disease franchises rather than stand-alone products”
Where a supplier can help
- Late-stage trial supplies and services
- Tied to the solid tumor Phase 3 starts and the in-house clinical organization: lab reagents, consumables, toxicology and trial logistics for a team running trials largely without CROs.
- Biologics manufacturing equipment
- Tied to the $300 million Hopewell expansion and the U.S. manufacturing agreement: process equipment, automation and validation services.
- Commercial launch support
- Tied to BEQALZI, MANGROVE in 1L MCL and TEVIMBRA's global expansion: market access, medical affairs and commercial data services in the U.S., Europe, Japan and Brazil.
- Pricing and reimbursement analytics
- Tied to IRA, Medicare Part D and China VBP pressures: health economics, contracting and gross-to-net tools.
- Supply chain resilience
- Tied to the dependence on CMOs and on three distributors: supplier-risk, dual-sourcing and distribution analytics offers.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like BeOne Medicines?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- Form 10-K for fiscal year 2025
- BeOne Medicines (formerly BeiGene) is a global oncology company, redomiciled from the Cayman Islands to Switzerland (registered office in Basel) in Q2 2025, with operations mainly through subsidiaries in the U.S., China, the UK and Australia; listed on Nasdaq, HKEx and the Shanghai STAR board; nearly 12,000 full-time employees (about 1,900 in the U.S.) as of February 13, 2026.
- FY2025 total revenue was $5.3 billion (+40.2%), with net income of $286.9 million (first year of GAAP and non-GAAP profit), operating cash flow of $1.1 billion and free cash flow of $941.7 million.
- BRUKINSA (zanubrutinib, BTK inhibitor) generated $3.9 billion (+48.6%): U.S. $2.8 billion (+45.1%), EU $596.4 million (+66.2%), China $344.1 million (+33.3%); it became the global market leader across B-cell malignancies in 2025 and is approved in 77 markets.
- TEVIMBRA (tislelizumab, anti-PD-1) sold $737.3 million (+18.8%); Amgen in-licensed products in China (XGEVA $306.0 million, BLINCYTO $104.2 million, KYPROLIS $75.0 million) keep growing.
- Revenue by geography: U.S. $2.88 billion, China $1.68 billion, Europe $611.4 million, rest of world $171.8 million; one reportable segment (pharmaceutical products).
- Strategy: build a CLL franchise on three mechanisms (BRUKINSA, the BCL2 inhibitor sonrotoclax first approved in China, the BTK degrader BGB-16673) and a solid tumor business on TEVIMBRA plus five NMEs that reached proof of concept in 2025; an in-house clinical team of about 3,800 people lets it run trials largely without CROs.
- R&D expense was $2.1 billion (+9.9%) and SG&A $2.1 billion (+13.7%); gross margin on product sales rose to 87.3% from 84.3%.
- Balance sheet: cash and cash equivalents of $4.5 billion and debt of $1.0 billion at December 31, 2025; $885 million upfront from Royalty Pharma for IMDELLTRA royalties; a HSBC-led Facilities Agreement refinanced about $768 million of short-term loans in November 2025.
- Key risks: competition in BTK and PD-1 classes, pricing and reimbursement (IRA in the U.S., NRDL and volume-based procurement in China), U.S.-China relations and PRC oversight, reliance on CMOs and on three distributors (Cencora 18.5%, McKesson 17.5%, Shanghai Pharmaceutical 10.1% of product revenue).
- Form 10-Q for the quarter ended September 30, 2026
- Q3 2026 total revenue was $1,889.8 million (+33.8%); nine-month revenue $5,108.3 million (+32.9%); BeOne Medicines is the former BeiGene, renamed and redomiciled to Switzerland in May 2025.
- BRUKINSA sold $1,390.9 million in the quarter (+33.7%): U.S. $1,005.1 million (+36.1%), Europe $217.6 million (+33.3%), China $103.1 million (+11.6%), rest of world $65.2 million (+40.4%).
- TEVIMBRA sold $243.3 million (+27.6%); Amgen products in China $167.0 million (+25.5%), driven by XGEVA volume; KYPROLIS fell 24.3%.
- Gross margin on product sales was 88.3% (85.9% a year earlier), after a $22.0 million impairment on the decision to discontinue promotion of POBEVCY.
- Income from operations was $418.7 million (+156.7%) and net income $384.7 million (+208.2%); diluted EPS $3.28 per ADS (non-GAAP $4.59).
- R&D rose 26.2% to $660.8 million (BTK CDAC, CDK4, PRMT5, GPC3x4-1BB programs); BeOne reached the Amgen co-funding cap in the quarter. SG&A was 32.0% of product sales versus 37.9%.
- Cash, cash equivalents and restricted cash were $5,866.3 million and total debt $1,074.1 million at September 30, 2026.
- Recent moves: a voluntary agreement with the U.S. government to expand access and strengthen U.S. manufacturing, FDA approval of TEVIMBRA plus ZIIHERA and chemotherapy in 1L HER2+ GEA, and a multi-part collaboration with Revolution Medicines including Asian rights to its RAS(ON) inhibitors.
- Third Quarter 2026 Financial Results and Business Updates (press release)
- Q3 2026 total revenue $1.9 billion (+34%), BRUKINSA $1.4 billion (+34%), U.S. BRUKINSA $1.0 billion (+36%); TEVIMBRA $243 million (+28%); Amgen in-licensed products $167 million (+26%).
- GAAP income from operations $418.7 million (+157%), adjusted $612.2 million (+79%); GAAP net income $385 million; diluted EPS per ADS $3.28 GAAP and $4.59 non-GAAP; free cash flow $474 million.
- FY2026 guidance raised: total revenue $6.9-7.0 billion (prior $6.6-6.8 billion), GAAP operating expenses $4.9-5.0 billion, GAAP operating income $1.2-1.3 billion, non-GAAP operating income $1.9-2.0 billion, gross margin in the high-80% range.
- The company expects to reverse certain tax valuation allowances in Q4 2026, giving a material tax benefit; about 118 million diluted ADSs expected.
- Pipeline: FDA Priority Review for the MANGROVE filing (BRUKINSA in 1L MCL); BEQALZI (sonrotoclax) now marketed; tacabrutideg (BTK CDAC) met its Phase 2 endpoint in R/R CLL, potential submission mid-2027; B7-H4 ADC started the Starstone-301 Phase 3 in ovarian cancer.
- Upcoming: GPC3x4-1BB bispecific Phase 3 and pivotal Phase 2 starts in HCC in Q4 2026, a 1L HCC Phase 3 in 1H 2027; China decisions on TEVIMBRA and ZIIHERA in 1L HER2+ GEA in 1H 2027.
- CEO John V. Oyler: results reflect "continued rapid global growth and leadership in hematology" and "one of the deepest pipelines in oncology".
- BeOne Medicines Q3 2026 earnings call transcript
- CEO John Oyler: "BeOne is executing at the very highest level in our history"; U.S. BRUKINSA sales passed $1 billion in a quarter for the first time, with global BRUKINSA sales of $1.4 billion (+34%).
- Oyler says six independent real-world CLL data sets give 21 hazard ratios that all favor BRUKINSA, with 16%-25% lower risk of death versus acalabrutinib in four large U.S. claims data sets.
- Solid tumors: differentiated data for five late-stage programs (GPC3 x 4-1BB, PRMT5, CEA ADC, CDK4, B7-H4 ADC); Oyler calls 2026 the promised "inflection year".
- CFO Aaron Rosenberg raised 2026 guidance to $6.9-7.0 billion revenue and $1.2-1.3 billion GAAP operating income; Q3 U.S. BRUKINSA had an approximate $50 million order-timing tailwind.
- Rosenberg: 2027 operating expense growth will be at least consistent with recent years, so margin expansion will be "modest" versus 2025 and 2026; a Medicare Part D liability increase turns a 2026 tailwind into a "flat to modest headwind" in 2027.
- Risks flagged: XGEVA biosimilars and potential VBP inclusion for XGEVA and KYPROLIS will likely pressure revenue beyond 2026.
- Tacabrutideg filing moved to mid-2027 after the FDA requested additional follow-up; CaDAnCe-304 versus pirtobrutinib upsized from 500 to 600 patients; KANDELA-302 (CDK4) upsized to 1,200 patients.
- Revolution Medicines partnership: BeOne runs the frontline colorectal 312 study and combines its PRMT5 and EGFR x MET x MET assets with RAS(ON) inhibitors.
- BeOne Medicines Q2 2026 earnings call transcript
- Q2 2026 (call of August 5, 2026): total revenue $1.7 billion (+30%), GAAP EPS $2.05 per ADS (+144%); BRUKINSA global revenue over $1.2 billion (+31%), U.S. $893 million (+31%).
- 2026 guidance raised by $300 million for revenue ($6.6-6.8 billion) and $250 million for GAAP operating income ($1.0-1.1 billion).
- Oyler: BRUKINSA is seeing "its highest level of sustained new patient starts" more than 6.5 years after launch, has treated more than 300,000 patients across 80-plus markets.
- FDA approved BEQALZI (sonrotoclax), "the first and only BCL-2 inhibitor in mantle cell lymphoma"; MANGROVE Phase 3 (BRUKINSA plus rituximab, 1L MCL) showed a 0.57 hazard ratio versus bendamustine-rituximab.
- A $300 million expansion of the Hopewell, New Jersey manufacturing site was announced.
- CELESTIAL-301 (zanubrutinib plus sonrotoclax versus VO) missed uMRD superiority; the study continues to its PFS endpoint and management remains "highly confident".
- Geography: U.S. about $899 million (+31%), China about $500 million (+17%), Europe about $208 million (+37%), rest of world about $73 million (more than doubled).
- Rosenberg: 2027 operating expenses expected to grow at a rate similar to the past two years; biosimilar competition for XGEVA could weigh beyond 2026.
Questions about BeOne Medicines
What does BeOne Medicines do?
BeOne Medicines, formerly BeiGene, is a global oncology company. Its main medicines are BRUKINSA for B-cell cancers and TEVIMBRA, an anti-PD-1 antibody, and it sells Amgen and other partners' products in China.
What is BeOne Medicines' revenue?
FY2025 total revenue was $5,343.0 million, up 40.2%. The company guides to $6.9-7.0 billion for 2026.
How many employees does BeOne Medicines have?
Nearly 12,000 full-time employees as of February 13, 2026, about 1,900 in the U.S.
Who leads BeOne Medicines?
John V. Oyler is Co-Founder, Chairman and CEO; Xiaobin Wu is President and COO and Aaron Rosenberg is CFO.
What is BeOne Medicines' strategy?
It aims to lead CLL with three mechanisms (BRUKINSA, BEQALZI, tacabrutideg), expand TEVIMBRA globally and build solid tumor franchises in breast, lung and gastrointestinal cancers.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)